PCIDB

KNApSAcK Metabolite C00000547

Metabolite

KNApSAcK Entry

id C00000547
Name Lovastatin / Monacolin K / (+)-Mevinolin
CAS RN 75330-75-5
Standard InChI InChI=1S/C24H36O5/c1-5-15(3)24(27)29-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-19-12-18(25)13-22(26)28-19/h6-7,10,14-16,18-21,23,25H,5,8-9,11-13H2,1-4H3/t14-,15-,16-,18+,19?,20-,21-,23-/m0/s1
Standard InChI (Main Layer) InChI=1S/C24H36O5/c1-5-15(3)24(27)29-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-19-12-18(25)13-22(26)28-19/h6-7,10,14-16,18-21,23,25H,5,8-9,11-13H2,1-4H3

Cluster

Phytochemical cluster
KCF-S cluster No. 1556

Link

ChEMBL

By standard InChI
By standard InChI Main Layer CHEMBL503 CHEMBL79583 CHEMBL333443 CHEMBL140273 CHEMBL167159 CHEMBL1230589 CHEMBL1394089 CHEMBL1515625

KEGG

By LinkDB C07074

CTD

By CAS RN D008148

Species

Summary

Plant class

class name count

Family

family name count
Aspergillaceae 1
Elaphomycetaceae 1

List (2)

* NCBI
KNApSAcK organism *ID *family *plant class *kingdom
Aspergillus terreus ATCC20542 5052 Aspergillaceae Fungi
Monascus ruber No. 1005 147546 Elaphomycetaceae Fungi

Human Protein / Gene in interaction

125 ChEMBL Protein in interactions

accession description class description compound assay ID (# of activities) # of diseases
(OMIM / KEGG)
P10635 Cytochrome P450 2D6 Cytochrome P450 2D6 CHEMBL503 CHEMBL1394089 CHEMBL1741321 (1) CHEMBL1909136 (2)
CHEMBL2071965 (1)
1 / 0
Q16637 Survival motor neuron protein Unclassified protein CHEMBL503 CHEMBL1613842 (1)
4 / 2
Q9Y6L6 Solute carrier organic anion transporter family member 1B1 Electrochemical transporter CHEMBL503 CHEMBL2076806 (1) CHEMBL2076963 (1)
CHEMBL2076968 (1) CHEMBL2078133 (1)
CHEMBL2169429 (1)
1 / 0
O94956 Solute carrier organic anion transporter family member 2B1 Unclassified protein CHEMBL503 CHEMBL2169431 (1)
0 / 0
P21728 D(1A) dopamine receptor Dopamine receptor CHEMBL503 CHEMBL1909139 (2)
0 / 0
P35354 Prostaglandin G/H synthase 2 Oxidoreductase CHEMBL503 CHEMBL1909131 (2)
0 / 3
Q12809 Potassium voltage-gated channel subfamily H member 2 KCNH, Kv10-12.x (Ether-a-go-go) CHEMBL503 CHEMBL1794573 (1) CHEMBL1909190 (2)
2 / 2
P08246 Neutrophil elastase S1A CHEMBL503 CHEMBL1909195 (2)
2 / 1
P33765 Adenosine receptor A3 Adenosine receptor CHEMBL503 CHEMBL1909215 (2)
0 / 0
Q16539 Mitogen-activated protein kinase 14 p38 CHEMBL503 CHEMBL1909201 (2)
0 / 0
P49146 Neuropeptide Y receptor type 2 Neuropeptide Y receptor CHEMBL503 CHEMBL1909176 (2)
0 / 0
P29466 Caspase-1 C14 CHEMBL503 CHEMBL1909193 (2)
0 / 0
P17252 Protein kinase C alpha type Alpha CHEMBL503 CHEMBL1909198 (2)
0 / 0
P27361 Mitogen-activated protein kinase 3 Erk CHEMBL503 CHEMBL1909199 (2)
0 / 0
Q03181 Peroxisome proliferator-activated receptor delta NR1C2 CHEMBL503 CHEMBL1794524 (1)
0 / 0
P14780 Matrix metalloproteinase-9 M10A CHEMBL503 CHEMBL1909197 (2)
2 / 2
Q13547 Histone deacetylase 1 Hydrolase CHEMBL503 CHEMBL2351478 (1)
0 / 0
P02545 Prelamin-A/C Unclassified protein CHEMBL503 CHEMBL1394089 CHEMBL1614544 (3)
11 / 10
P16473 Thyrotropin receptor Glycohormone receptor CHEMBL503 CHEMBL1614281 (1) CHEMBL1614361 (1)
3 / 2
P19793 Retinoic acid receptor RXR-alpha NR2B1 CHEMBL503 CHEMBL1794471 (1)
0 / 0
P00918 Carbonic anhydrase 2 Lyase CHEMBL503 CHEMBL1909123 (2)
1 / 2
P07550 Beta-2 adrenergic receptor Adrenergic receptor CHEMBL503 CHEMBL1909092 (2)
0 / 1
P21397 Amine oxidase [flavin-containing] A Oxidoreductase CHEMBL503 CHEMBL1909169 (2)
1 / 1
P25021 Histamine H2 receptor Histamine receptor CHEMBL503 CHEMBL1909157 (2)
0 / 0
P35367 Histamine H1 receptor Histamine receptor CHEMBL503 CHEMBL1909156 (2)
0 / 0
Q01959 Sodium-dependent dopamine transporter Dopamine CHEMBL503 CHEMBL1909143 (2)
1 / 0
P08912 Muscarinic acetylcholine receptor M5 Acetylcholine receptor CHEMBL503 CHEMBL1909174 (2)
0 / 0
P18825 Alpha-2C adrenergic receptor Adrenergic receptor CHEMBL503 CHEMBL1909090 (2)
0 / 0
P13945 Beta-3 adrenergic receptor Adrenergic receptor CHEMBL503 CHEMBL1909093 (2)
0 / 0
Q16850 Lanosterol 14-alpha demethylase Cytochrome P450 51A1 CHEMBL503 CHEMBL934981 (1)
0 / 0
P08183 Multidrug resistance protein 1 drug CHEMBL503 CHEMBL2077112 (1) CHEMBL2077341 (1)
CHEMBL2077344 (1) CHEMBL2075162 (1)
CHEMBL2076213 (1) CHEMBL2076214 (1)
CHEMBL2078148 (1)
1 / 0
P25024 C-X-C chemokine receptor type 1 CXC chemokine receptor CHEMBL503 CHEMBL1909127 (2)
0 / 0
P06241 Tyrosine-protein kinase Fyn Src CHEMBL503 CHEMBL1909204 (2)
0 / 0
Q08209 Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform Ser_Thr CHEMBL503 CHEMBL1909202 (2)
0 / 0
P11712 Cytochrome P450 2C9 Cytochrome P450 2C9 CHEMBL503 CHEMBL1394089 CHEMBL1741325 (1) CHEMBL1909135 (2)
CHEMBL2071963 (1)
0 / 1
P00533 Epidermal growth factor receptor TK tyrosine-protein kinase EGFR subfamily CHEMBL503 CHEMBL1909203 (2)
1 / 11
P11473 Vitamin D3 receptor NR1I1 CHEMBL503 CHEMBL1515625 CHEMBL1794311 (3)
2 / 3
P14416 D(2) dopamine receptor Dopamine receptor CHEMBL503 CHEMBL1909140 (2)
2 / 0
P23219 Prostaglandin G/H synthase 1 Oxidoreductase CHEMBL503 CHEMBL1909130 (2)
0 / 0
P37288 Vasopressin V1a receptor Vasopressin and oxytocin receptor CHEMBL503 CHEMBL1909120 (2)
0 / 0
P41145 Kappa-type opioid receptor Opioid receptor CHEMBL503 CHEMBL1909181 (2)
0 / 0
Q9Y271 Cysteinyl leukotriene receptor 1 Leukotriene receptor CHEMBL503 CHEMBL1909164 (2)
0 / 0
P20701 Integrin alpha-L Membrane receptor CHEMBL503 CHEMBL700600 (1) CHEMBL2317562 (1)
0 / 0
P29274 Adenosine receptor A2a Adenosine receptor CHEMBL503 CHEMBL1909214 (2)
0 / 0
P25929 Neuropeptide Y receptor type 1 Neuropeptide Y receptor CHEMBL503 CHEMBL1909175 (2)
0 / 0
P50052 Type-2 angiotensin II receptor Angiotensin receptor CHEMBL503 CHEMBL1909096 (2)
1 / 1
P17948 Vascular endothelial growth factor receptor 1 Vegfr CHEMBL503 CHEMBL1909118 (2)
0 / 0
P41968 Melanocortin receptor 3 Melanocortin receptor CHEMBL503 CHEMBL1909166 (2)
1 / 0
Q92769 Histone deacetylase 2 Hydrolase CHEMBL503 CHEMBL2351477 (1)
0 / 0
P11509 Cytochrome P450 2A6 Cytochrome P450 2A6 CHEMBL503 CHEMBL1909133 (2)
0 / 0
Q16665 Hypoxia-inducible factor 1-alpha Transcription Factor CHEMBL503 CHEMBL1394089 CHEMBL1614456 (2) CHEMBL1613803 (2)
CHEMBL1614399 (1)
0 / 0
Q92830 Histone acetyltransferase KAT2A Enzyme CHEMBL1394089 CHEMBL1738606 (1)
0 / 0
P17301 Integrin alpha-2 Unclassified protein CHEMBL503 CHEMBL2317564 (1)
0 / 0
P84022 Mothers against decapentaplegic homolog 3 Unclassified protein CHEMBL503 CHEMBL1794584 (2)
2 / 0
O75496 Geminin Unclassified protein CHEMBL503 CHEMBL2114843 (2) CHEMBL2114780 (2)
0 / 0
P46721 Solute carrier organic anion transporter family member 1A2 Unclassified protein CHEMBL503 CHEMBL2076553 (1)
0 / 0
P04035 3-hydroxy-3-methylglutaryl-coenzyme A reductase Oxidoreductase CHEMBL503 CHEMBL79583 CHEMBL687156 (1) CHEMBL687157 (1)
CHEMBL692247 (1) CHEMBL692248 (1)
CHEMBL692133 (1) CHEMBL692721 (1)
CHEMBL692723 (1) CHEMBL692725 (1)
CHEMBL692726 (1) CHEMBL690061 (1)
CHEMBL690062 (1) CHEMBL991179 (2)
CHEMBL1833416 (1) CHEMBL1833417 (1)
CHEMBL1833418 (1) CHEMBL1833419 (1)
CHEMBL1833420 (1) CHEMBL1833421 (1)
CHEMBL1833422 (1) CHEMBL1909158 (2)
CHEMBL1918949 (1) CHEMBL1918950 (1)
CHEMBL1918951 (1) CHEMBL1918952 (1)
CHEMBL1918953 (1) CHEMBL2351234 (1)
CHEMBL2351479 (1)
0 / 0
P08913 Alpha-2A adrenergic receptor Adrenergic receptor CHEMBL503 CHEMBL1909088 (2)
0 / 0
P21917 D(4) dopamine receptor Dopamine receptor CHEMBL503 CHEMBL1909142 (2)
0 / 0
P30988 Calcitonin receptor Calcitonin receptor CHEMBL503 CHEMBL1909101 (2)
0 / 0
P35462 D(3) dopamine receptor Dopamine receptor CHEMBL503 CHEMBL1909141 (2)
1 / 0
P41143 Delta-type opioid receptor Opioid receptor CHEMBL503 CHEMBL1909180 (2)
0 / 0
Q92731 Estrogen receptor beta NR3A2 CHEMBL503 CHEMBL1909146 (2)
0 / 1
P41595 5-hydroxytryptamine receptor 2B Serotonin receptor CHEMBL503 CHEMBL1909104 (2)
0 / 0
P25101 Endothelin-1 receptor Endothelin receptor CHEMBL503 CHEMBL1909144 (2)
0 / 0
P30411 B2 bradykinin receptor Bradykinin receptor CHEMBL503 CHEMBL1909100 (2)
0 / 0
P32245 Melanocortin receptor 4 Melanocortin receptor CHEMBL503 CHEMBL1909167 (2)
1 / 0
P32238 Cholecystokinin receptor type A Cholecystokinin receptor CHEMBL503 CHEMBL1909129 (2)
0 / 0
P08311 Cathepsin G S1A CHEMBL503 CHEMBL1909194 (2)
0 / 0
Q99720 Sigma non-opioid intracellular receptor 1 Membrane receptor CHEMBL503 CHEMBL1909110 (2)
1 / 0
P03956 Interstitial collagenase M10A CHEMBL503 CHEMBL1909196 (2)
0 / 1
P32241 Vasoactive intestinal polypeptide receptor 1 Vasoactive intestinal peptide receptor CHEMBL503 CHEMBL1909119 (2)
0 / 0
Q9NPD5 Solute carrier organic anion transporter family member 1B3 Electrochemical transporter CHEMBL503 CHEMBL2169430 (1)
1 / 0
O94782 Ubiquitin carboxyl-terminal hydrolase 1 Enzyme CHEMBL503 CHEMBL1515625 CHEMBL1794467 (2)
0 / 0
P04150 Glucocorticoid receptor NR3C1 CHEMBL503 CHEMBL1794382 (1) CHEMBL1909150 (2)
0 / 1
P08172 Muscarinic acetylcholine receptor M2 Acetylcholine receptor CHEMBL503 CHEMBL1909171 (2)
2 / 0
P11229 Muscarinic acetylcholine receptor M1 Acetylcholine receptor CHEMBL503 CHEMBL1909170 (2)
0 / 0
P14324 Farnesyl pyrophosphate synthase Transferase CHEMBL503 CHEMBL1250628 (1)
0 / 0
P21554 Cannabinoid receptor 1 Cannabinoid receptor CHEMBL503 CHEMBL1909122 (2)
0 / 0
P31645 Sodium-dependent serotonin transporter Serotonin CHEMBL503 CHEMBL1909109 (2)
2 / 0
P37231 Peroxisome proliferator-activated receptor gamma NR1C3 CHEMBL503 CHEMBL1794510 (1)
5 / 3
P04626 Receptor tyrosine-protein kinase erbB-2 TK tyrosine-protein kinase EGFR subfamily CHEMBL503 CHEMBL1909205 (2)
5 / 10
P20309 Muscarinic acetylcholine receptor M3 Acetylcholine receptor CHEMBL503 CHEMBL1909172 (2)
1 / 0
P21452 Substance-K receptor Neurokinin receptor CHEMBL503 CHEMBL1909114 (2)
0 / 0
P51679 C-C chemokine receptor type 4 CC chemokine receptor CHEMBL503 CHEMBL1909125 (2)
0 / 0
P51681 C-C chemokine receptor type 5 CC chemokine receptor CHEMBL503 CHEMBL1909126 (2)
3 / 0
P50406 5-hydroxytryptamine receptor 6 Serotonin receptor CHEMBL503 CHEMBL1909108 (2)
0 / 0
P41597 C-C chemokine receptor type 2 CC chemokine receptor CHEMBL503 CHEMBL1909124 (2)
1 / 0
P28482 Mitogen-activated protein kinase 1 Erk CHEMBL503 CHEMBL1230589 CHEMBL1613808 (1) CHEMBL1909200 (2)
0 / 0
P08575 Receptor-type tyrosine-protein phosphatase C Enzyme CHEMBL503 CHEMBL1909207 (2)
2 / 1
P05177 Cytochrome P450 1A2 Cytochrome P450 1A2 CHEMBL503 CHEMBL1394089 CHEMBL1741322 (1) CHEMBL1909132 (2)
CHEMBL2071962 (1)
0 / 0
Q92887 Canalicular multispecific organic anion transporter 1 Unclassified protein CHEMBL503 CHEMBL2078137 (1)
1 / 1
P51449 Nuclear receptor ROR-gamma Nuclear hormone receptor subfamily 1 group F member 3 CHEMBL503 CHEMBL2114842 (1)
0 / 0
O76074 cGMP-specific 3',5'-cyclic phosphodiesterase PDE_5A CHEMBL503 CHEMBL1909186 (2)
0 / 0
P03372 Estrogen receptor NR3A1 CHEMBL503 CHEMBL1909145 (2)
1 / 1
P08588 Beta-1 adrenergic receptor Adrenergic receptor CHEMBL503 CHEMBL1909091 (2)
1 / 0
P22303 Acetylcholinesterase Hydrolase CHEMBL503 CHEMBL1909212 (2)
1 / 0
P28223 5-hydroxytryptamine receptor 2A Serotonin receptor CHEMBL503 CHEMBL1909211 (2)
0 / 0
P28335 5-hydroxytryptamine receptor 2C Serotonin receptor CHEMBL503 CHEMBL1909105 (2)
0 / 0
P35372 Mu-type opioid receptor Opioid receptor CHEMBL503 CHEMBL1909182 (2)
0 / 0
P08173 Muscarinic acetylcholine receptor M4 Acetylcholine receptor CHEMBL503 CHEMBL1909173 (2)
0 / 0
P25103 Substance-P receptor Neurokinin receptor CHEMBL503 CHEMBL1909113 (2)
0 / 0
P25105 Platelet-activating factor receptor PAF receptor CHEMBL503 CHEMBL1909187 (2)
0 / 0
P33032 Melanocortin receptor 5 Melanocortin receptor CHEMBL503 CHEMBL1909168 (2)
0 / 0
P16050 Arachidonate 15-lipoxygenase Enzyme CHEMBL503 CHEMBL1614240 (1)
0 / 0
P31749 RAC-alpha serine/threonine-protein kinase Akt CHEMBL503 CHEMBL952473 (1)
4 / 1
P33261 Cytochrome P450 2C19 Cytochrome P450 2C19 CHEMBL503 CHEMBL1394089 CHEMBL1741323 (1) CHEMBL1909134 (2)
CHEMBL2071964 (1)
1 / 1
P08684 Cytochrome P450 3A4 Cytochrome P450 3A4 CHEMBL503 CHEMBL1394089 CHEMBL1515625 CHEMBL1614108 (3) CHEMBL1613886 (3)
CHEMBL1741324 (1) CHEMBL1743273 (1)
CHEMBL1743290 (1) CHEMBL1909138 (2)
CHEMBL2071966 (1) CHEMBL2071967 (1)
0 / 1
P05181 Cytochrome P450 2E1 Cytochrome P450 2E1 CHEMBL503 CHEMBL1909137 (2)
0 / 0
P10636 Microtubule-associated protein tau Unclassified protein CHEMBL503 CHEMBL1614421 (1)
4 / 3
Q16236 Nuclear factor erythroid 2-related factor 2 Unclassified protein CHEMBL503 CHEMBL1738184 (1) CHEMBL2114890 (1)
0 / 0
P23975 Sodium-dependent noradrenaline transporter Norepinephrine CHEMBL503 CHEMBL1909094 (2)
1 / 1
P25100 Alpha-1D adrenergic receptor Adrenergic receptor CHEMBL503 CHEMBL1909087 (2)
0 / 0
P30542 Adenosine receptor A1 Adenosine receptor CHEMBL503 CHEMBL1909213 (2)
0 / 0
P18089 Alpha-2B adrenergic receptor Adrenergic receptor CHEMBL503 CHEMBL1909089 (2)
0 / 0
P24557 Thromboxane-A synthase Cytochrome P450 5A1 CHEMBL503 CHEMBL1909116 (2)
1 / 1
P06239 Tyrosine-protein kinase Lck Src CHEMBL503 CHEMBL1909206 (2)
0 / 1
P25025 C-X-C chemokine receptor type 2 CXC chemokine receptor CHEMBL503 CHEMBL1909128 (2)
0 / 0
P05362 Intercellular adhesion molecule 1 Adhesion CHEMBL503 CHEMBL700600 (1) CHEMBL998767 (1)
CHEMBL998768 (1) CHEMBL998769 (1)
CHEMBL998770 (1) CHEMBL998771 (1)
1 / 2
Q9UBN7 Histone deacetylase 6 Hydrolase CHEMBL503 CHEMBL2351235 (1)
0 / 0
B2RXH2 Lysine-specific demethylase 4E Enzyme CHEMBL503 CHEMBL1613914 (1)
0 / 0
Q96KQ7 Histone-lysine N-methyltransferase EHMT2 Enzyme CHEMBL503 CHEMBL1738442 (2)
0 / 0
Q9NUW8 Tyrosyl-DNA phosphodiesterase 1 Enzyme CHEMBL503 CHEMBL1614364 (1)
1 / 1
O75874 Isocitrate dehydrogenase [NADP] cytoplasmic Enzyme CHEMBL503 CHEMBL1964002 (1) CHEMBL2354311 (2)
1 / 0
P05107 Integrin beta-2 Membrane receptor CHEMBL503 CHEMBL700600 (1)
1 / 1

CTD interaction (128)

compound gene gene name gene description interaction interaction type form reference
pmid
D008148 19 ABCA1
ABC-1
ABC1
CERP
HDLDT1
TGD
ATP-binding cassette, sub-family A (ABC1), member 1 Lovastatin results in increased expression of ABCA1 mRNA increases expression
mRNA 19260826
D008148 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) ABCB1 protein results in increased transport of Lovastatin increases transport
protein 15616150
D008148 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) ABCB1 protein results in increased transport of Lovastatin analog increases transport
protein 15616150
D008148 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) Lovastatin analog inhibits the reaction [ABCB1 protein results in increased transport of calcein AM] decreases reaction
/ increases transport
protein 15616150
D008148 5243 ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (EC:3.6.3.44) Lovastatin analog results in decreased activity of ABCB1 protein decreases activity
protein 15616150
D008148 1244 ABCC2
ABC30
CMOAT
DJS
MRP2
cMRP
ATP-binding cassette, sub-family C (CFTR/MRP), member 2 Lovastatin analog inhibits the reaction [ABCC2 protein results in increased transport of calcein AM] decreases reaction
/ increases transport
protein 15616150
D008148 1244 ABCC2
ABC30
CMOAT
DJS
MRP2
cMRP
ATP-binding cassette, sub-family C (CFTR/MRP), member 2 Lovastatin analog results in decreased activity of ABCC2 protein decreases activity
protein 15616150
D008148 59 ACTA2
AAT6
ACTSA
MYMY5
actin, alpha 2, smooth muscle, aorta Lovastatin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] decreases reaction
/ increases expression
protein 22129737
D008148 59 ACTA2
AAT6
ACTSA
MYMY5
actin, alpha 2, smooth muscle, aorta Lovastatin results in decreased expression of ACTA2 protein decreases expression
protein 22129737
D008148 9465 AKAP7
AKAP15
AKAP18
A kinase (PRKA) anchor protein 7 AKAP7 SNP results in decreased susceptibility to Lovastatin decreases response to substance
SNP 21483694
D008148 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein] decreases reaction
/ increases phosphorylation
protein 19760159
D008148 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) Lovastatin results in decreased phosphorylation of AKT1 protein decreases phosphorylation
protein 16425225
17472962
D008148 287 ANK2
ANK-2
LQT4
brank-2
ankyrin 2, neuronal ANK2 SNP results in decreased susceptibility to Lovastatin decreases response to substance
SNP 21483694
D008148 335 APOA1
apolipoprotein A-I [Lovastatin co-treated with Niacin] results in increased expression of APOA1 protein affects cotreatment
/ increases expression
protein 17319473
D008148 335 APOA1
apolipoprotein A-I [Niacin co-treated with Lovastatin] results in increased expression of APOA1 protein affects cotreatment
/ increases expression
protein 12633795
D008148 338 APOB
FLDB
LDLCQ4
apolipoprotein B Lovastatin results in decreased secretion of APOB protein decreases secretion
protein 11728391
D008148 338 APOB
FLDB
LDLCQ4
apolipoprotein B [Niacin co-treated with Lovastatin] results in decreased expression of APOB protein affects cotreatment
/ decreases expression
protein 12633795
D008148 581 BAX
BCL2L4
BCL2-associated X protein Lovastatin results in increased expression of BAX protein increases expression
protein 10473109
D008148 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 Lovastatin results in decreased expression of BCL2 protein decreases expression
protein 10473109
12094262
D008148 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 Mevalonic Acid inhibits the reaction [Lovastatin results in decreased expression of BCL2 protein] decreases expression
/ decreases reaction
protein 12094262
D008148 10018 BCL2L11
BAM
BIM
BOD
BCL2-like 11 (apoptosis facilitator) anthra(1,9-cd)pyrazol-6(2H)-one inhibits the reaction [Lovastatin results in increased expression of BCL2L11 protein] decreases reaction
/ increases expression
protein 18766339
D008148 10018 BCL2L11
BAM
BIM
BOD
BCL2-like 11 (apoptosis facilitator) Lovastatin results in increased expression of BCL2L11 protein increases expression
protein 18766339
D008148 332 BIRC5
API4
EPR-1
baculoviral IAP repeat containing 5 farnesyl pyrophosphate inhibits the reaction [Lovastatin results in decreased expression of BIRC5 protein] decreases expression
/ decreases reaction
protein 17472962
D008148 332 BIRC5
API4
EPR-1
baculoviral IAP repeat containing 5 geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in decreased expression of BIRC5 protein] decreases expression
/ decreases reaction
protein 17472962
D008148 332 BIRC5
API4
EPR-1
baculoviral IAP repeat containing 5 Lovastatin results in decreased expression of BIRC5 protein decreases expression
protein 17472962
18815881
D008148 835 CASP2
CASP-2
ICH1
NEDD-2
NEDD2
PPP1R57
caspase 2, apoptosis-related cysteine peptidase (EC:3.4.22.55) Lovastatin results in increased activity of CASP2 protein increases activity
protein 12933658
D008148 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) farnesyl pyrophosphate inhibits the reaction [Lovastatin results in increased activity of and results in increased cleavage of CASP3 protein] decreases reaction
/ increases activity
/ increases cleavage
protein 18766339
D008148 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased activity of and results in increased cleavage of CASP3 protein] decreases reaction
/ increases activity
/ increases cleavage
protein 18766339
D008148 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Lovastatin results in increased activity of CASP3 protein increases activity
protein 11720884
12933658
18034278
18766339
D008148 839 CASP6
MCH2
caspase 6, apoptosis-related cysteine peptidase (EC:3.4.22.59) Lovastatin results in increased activity of CASP6 protein increases activity
protein 11720884
D008148 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) Lovastatin results in increased activity of CASP8 protein increases activity
protein 15705602
D008148 842 CASP9
APAF-3
APAF3
ICE-LAP6
MCH6
PPP1R56
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) Lovastatin results in increased activity of CASP9 protein increases activity
protein 12933658
15705602
D008148 595 CCND1
BCL1
D11S287E
PRAD1
U21B31
cyclin D1 Lovastatin results in decreased expression of CCND1 protein decreases expression
protein 18034278
D008148 896 CCND3
cyclin D3 Lovastatin results in decreased expression of CCND3 protein decreases expression
protein 10502407
D008148 960 CD44
CDW44
CSPG8
ECMR-III
HCELL
HUTCH-I
IN
LHR
MC56
MDU2
MDU3
MIC4
Pgp1
CD44 molecule (Indian blood group) Lovastatin results in decreased expression of CD44 mRNA decreases expression
mRNA 21199873
D008148 960 CD44
CDW44
CSPG8
ECMR-III
HCELL
HUTCH-I
IN
LHR
MC56
MDU2
MDU3
MIC4
Pgp1
CD44 molecule (Indian blood group) Lovastatin results in decreased expression of CD44 protein decreases expression
protein 21199873
D008148 998 CDC42
CDC42Hs
G25K
cell division cycle 42 Lovastatin results in increased expression of CDC42 protein increases expression
protein 18766339
D008148 1017 CDK2
p33(CDK2)
cyclin-dependent kinase 2 (EC:2.7.11.22) Lovastatin results in decreased activity of CDK2 protein decreases activity
protein 10502407
D008148 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) Lovastatin results in increased expression of CDKN1A protein increases expression
protein 18034278
D008148 1027 CDKN1B
CDKN4
KIP1
MEN1B
MEN4
P27KIP1
cyclin-dependent kinase inhibitor 1B (p27, Kip1) Lovastatin results in increased expression of CDKN1B protein increases expression
protein 10502407
15118409
18034278
D008148 1063 CENPF
CENF
PRO1779
hcp-1
centromere protein F, 350/400kDa Lovastatin promotes the reaction [Paclitaxel results in increased expression of CENPF protein] increases expression
/ increases reaction
protein 12467231
D008148 1063 CENPF
CENF
PRO1779
hcp-1
centromere protein F, 350/400kDa Lovastatin results in increased expression of CENPF protein increases expression
protein 12467231
D008148 1063 CENPF
CENF
PRO1779
hcp-1
centromere protein F, 350/400kDa Mevalonic Acid inhibits the reaction [Lovastatin results in increased expression of CENPF protein] decreases reaction
/ increases expression
protein 12467231
D008148 1111 CHEK1
CHK1
checkpoint kinase 1 (EC:2.7.11.1) Lovastatin inhibits the reaction [Cisplatin results in increased phosphorylation of CHEK1 protein] decreases reaction
/ increases phosphorylation
protein 21356574
D008148 1111 CHEK1
CHK1
checkpoint kinase 1 (EC:2.7.11.1) Lovastatin inhibits the reaction [Doxorubicin results in increased phosphorylation of CHEK1 protein] decreases reaction
/ increases phosphorylation
protein 17088865
21356574
D008148 1499 CTNNB1
CTNNB
MRD19
armadillo
catenin (cadherin-associated protein), beta 1, 88kDa Lovastatin affects the localization of and results in increased expression of CTNNB1 protein affects localization
/ increases expression
protein 17234346
D008148 1558 CYP2C8
CPC8
CYPIIC8
MP-12/MP-20
cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) Lovastatin results in decreased activity of CYP2C8 protein decreases activity
protein 15601807
D008148 1576 CYP3A4
CP33
CP34
CYP3A
CYP3A3
CYPIIIA3
CYPIIIA4
HLP
NF-25
P450C3
P450PCN1
cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) [Lovastatin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA increases activity
/ increases expression
mRNA 17041008
D008148 1576 CYP3A4
CP33
CP34
CYP3A
CYP3A3
CYPIIIA3
CYPIIIA4
HLP
NF-25
P450C3
P450PCN1
cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) Lovastatin results in increased expression of CYP3A4 mRNA increases expression
mRNA 12505310
D008148 55840 EAF2
BM040
TRAITS
U19
ELL associated factor 2 EAF2 SNP results in decreased susceptibility to Lovastatin decreases response to substance
SNP 21483694
D008148 1950 EGF
HOMG4
URG
epidermal growth factor Lovastatin inhibits the reaction [EGF protein promotes the reaction [EGFR protein results in increased phosphorylation of EGFR protein]] decreases reaction
/ increases phosphorylation
/ increases reaction
protein 12942316
D008148 1950 EGF
HOMG4
URG
epidermal growth factor Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein] decreases reaction
/ increases phosphorylation
protein 19760159
D008148 1950 EGF
HOMG4
URG
epidermal growth factor Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] decreases reaction
/ increases phosphorylation
protein 19760159
D008148 1950 EGF
HOMG4
URG
epidermal growth factor Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein] decreases reaction
/ increases phosphorylation
protein 19760159
D008148 1950 EGF
HOMG4
URG
epidermal growth factor Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein] decreases reaction
/ increases phosphorylation
protein 19760159
D008148 1950 EGF
HOMG4
URG
epidermal growth factor Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of RAF1 protein] decreases reaction
/ increases phosphorylation
protein 19760159
D008148 1956 EGFR
ERBB
ERBB1
HER1
PIG61
mENA
epidermal growth factor receptor (EC:2.7.10.1) Lovastatin inhibits the reaction [EGF protein promotes the reaction [EGFR protein results in increased phosphorylation of EGFR protein]] decreases reaction
/ increases phosphorylation
/ increases reaction
protein 12942316
D008148 1956 EGFR
ERBB
ERBB1
HER1
PIG61
mENA
epidermal growth factor receptor (EC:2.7.10.1) Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] decreases reaction
/ increases phosphorylation
protein 19760159
D008148 355 FAS
ALPS1A
APO-1
APT1
CD95
FAS1
FASTM
TNFRSF6
Fas cell surface death receptor Lovastatin inhibits the reaction [Doxorubicin results in increased expression of FAS mRNA] decreases reaction
/ increases expression
mRNA 17088865
D008148 356 FASLG
ALPS1B
APT1LG1
APTL
CD178
CD95-L
CD95L
FASL
TNFSF6
Fas ligand (TNF superfamily, member 6) Lovastatin inhibits the reaction [Doxorubicin results in increased expression of FASLG mRNA] decreases reaction
/ increases expression
mRNA 17088865
D008148 2194 FASN
FAS
OA-519
SDR27X1
fatty acid synthase (EC:2.3.1.85 2.3.1.38 2.3.1.39 2.3.1.41 3.1.2.14 4.2.1.59 1.1.1.100 1.3.1.39) Lovastatin results in increased expression of FASN mRNA increases expression
mRNA 11728391
D008148 2222 FDFT1
DGPT
ERG9
SQS
SS
farnesyl-diphosphate farnesyltransferase 1 (EC:2.5.1.21) Lovastatin results in increased activity of FDFT1 protein increases activity
protein 8517861
D008148 2596 GAP43
B-50
PP46
growth associated protein 43 Lovastatin results in increased expression of GAP43 protein increases expression
protein 20694854
D008148 2932 GSK3B
glycogen synthase kinase 3 beta (EC:2.7.11.1 2.7.11.26) Lovastatin results in decreased phosphorylation of GSK3B protein decreases phosphorylation
protein 17234346
D008148 3014 H2AFX
H2A.X
H2A/X
H2AX
H2A histone family, member X Lovastatin inhibits the reaction [Cisplatin results in increased phosphorylation of H2AFX protein] decreases reaction
/ increases phosphorylation
protein 21356574
D008148 3156 HMGCR
LDLCQ3
3-hydroxy-3-methylglutaryl-CoA reductase (EC:1.1.1.34) Lovastatin inhibits the reaction [HMGCR protein results in increased abundance of geranyl diphosphate] decreases reaction
/ increases abundance
protein 19856009
D008148 3156 HMGCR
LDLCQ3
3-hydroxy-3-methylglutaryl-CoA reductase (EC:1.1.1.34) Lovastatin results in decreased activity of HMGCR protein decreases activity
protein 8593127
17208200
19699819
D008148 3156 HMGCR
LDLCQ3
3-hydroxy-3-methylglutaryl-CoA reductase (EC:1.1.1.34) [Lovastatin results in decreased activity of HMGCR protein] which results in decreased abundance of farnesyl pyrophosphate decreases abundance
/ decreases activity
protein 17208200
D008148 3156 HMGCR
LDLCQ3
3-hydroxy-3-methylglutaryl-CoA reductase (EC:1.1.1.34) [Lovastatin results in decreased activity of HMGCR protein] which results in decreased abundance of geranylgeranyl pyrophosphate decreases abundance
/ decreases activity
protein 17208200
D008148 3156 HMGCR
LDLCQ3
3-hydroxy-3-methylglutaryl-CoA reductase (EC:1.1.1.34) Lovastatin results in increased expression of HMGCR mRNA increases expression
mRNA 8517861
19260826
D008148 3162 HMOX1
HMOX1D
HO-1
HSP32
bK286B10
heme oxygenase (decycling) 1 (EC:1.14.99.3) Lovastatin results in increased expression of HMOX1 protein increases expression
protein 20594940
21910007
D008148 3265 HRAS
C-BAS/HAS
C-H-RAS
C-HA-RAS1
CTLO
H-RASIDX
HAMSV
HRAS1
K-RAS
N-RAS
RASH1
Harvey rat sarcoma viral oncogene homolog Lovastatin results in decreased prenylation of and results in decreased localization of HRAS protein decreases localization
/ decreases prenylation
protein 19360310
D008148 3265 HRAS
C-BAS/HAS
C-H-RAS
C-HA-RAS1
CTLO
H-RASIDX
HAMSV
HRAS1
K-RAS
N-RAS
RASH1
Harvey rat sarcoma viral oncogene homolog Lovastatin results in decreased prenylation of HRAS protein decreases prenylation
protein 16156861
D008148 3638 INSIG1
CL-6
CL6
insulin induced gene 1 Lovastatin results in increased expression of INSIG1 mRNA increases expression
mRNA 19260826
D008148 3845 KRAS
C-K-RAS
CFC2
K-RAS2A
K-RAS2B
K-RAS4A
K-RAS4B
KI-RAS
KRAS1
KRAS2
NS
NS3
RASK2
Kirsten rat sarcoma viral oncogene homolog Lovastatin results in decreased prenylation of KRAS protein decreases prenylation
protein 16156861
D008148 3949 LDLR
FH
FHC
LDLCQ2
low density lipoprotein receptor Lovastatin results in increased activity of LDLR protein increases activity
protein 8593127
11728391
D008148 3949 LDLR
FH
FHC
LDLCQ2
low density lipoprotein receptor Lovastatin results in increased expression of LDLR mRNA increases expression
mRNA 11728391
12524230
D008148 3949 LDLR
FH
FHC
LDLCQ2
low density lipoprotein receptor Oncostatin M promotes the reaction [Lovastatin results in increased expression of LDLR mRNA] increases expression
/ increases reaction
mRNA 12524230
D008148 51176 LEF1
LEF-1
TCF10
TCF1ALPHA
TCF7L3
lymphoid enhancer-binding factor 1 Lovastatin affects the localization of LEF1 protein affects localization
protein 17234346
D008148 4001 LMNB1
ADLD
LMN
LMN2
LMNB
lamin B1 Lovastatin affects the localization of LMNB1 protein affects localization
protein 11720884
D008148 4001 LMNB1
ADLD
LMN
LMN2
LMNB
lamin B1 Lovastatin results in decreased farnesylation of LMNB1 protein decreases farnesylation
protein 10203554
D008148 4001 LMNB1
ADLD
LMN
LMN2
LMNB
lamin B1 Lovastatin results in increased degradation of LMNB1 protein increases degradation
protein 11720884
D008148 4018 LPA
AK38
APOA
LP
lipoprotein, Lp(a) (EC:3.4.21.-) [Lovastatin co-treated with Niacin] results in decreased expression of LPA protein affects cotreatment
/ decreases expression
protein 17319473
D008148 4018 LPA
AK38
APOA
LP
lipoprotein, Lp(a) (EC:3.4.21.-) [Niacin co-treated with Lovastatin] results in decreased expression of LPA protein affects cotreatment
/ decreases expression
protein 12633795
D008148 9663 LPIN2
lipin 2 (EC:3.1.3.4) LPIN2 SNP results in decreased susceptibility to Lovastatin decreases response to substance
SNP 21483694
D008148 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein] decreases reaction
/ increases phosphorylation
protein 19760159
D008148 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) Lovastatin results in decreased activity of MAPK1 protein decreases activity
protein 19360310
D008148 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein] decreases reaction
/ increases phosphorylation
protein 19760159
D008148 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) Lovastatin results in decreased activity of MAPK3 protein decreases activity
protein 19360310
D008148 4313 MMP2
CLG4
CLG4A
MMP-II
MONA
TBE-1
matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) (EC:3.4.24.24) Lovastatin results in decreased expression of MMP2 protein decreases expression
protein 19360310
D008148 4318 MMP9
CLG4B
GELB
MANDP2
MMP-9
matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) (EC:3.4.24.35) Lovastatin results in decreased expression of MMP9 protein decreases expression
protein 19360310
D008148 8856 NR1I2
BXR
ONR1
PAR
PAR1
PAR2
PARq
PRR
PXR
SAR
SXR
nuclear receptor subfamily 1, group I, member 2 [Lovastatin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA increases activity
/ increases expression
protein 17041008
D008148 4893 NRAS
ALPS4
N-ras
NRAS1
NS6
neuroblastoma RAS viral (v-ras) oncogene homolog Lovastatin results in decreased prenylation of NRAS protein decreases prenylation
protein 16156861
D008148 29780 PARVB
CGI-56
parvin, beta PARVB SNP results in decreased susceptibility to Lovastatin decreases response to substance
SNP 21483694
D008148 5446 PON3
paraoxonase 3 (EC:3.1.1.2 3.1.8.1 3.1.1.81) PON3 protein results in increased hydrolysis of Lovastatin increases hydrolysis
protein 15772423
D008148 5468 PPARG
CIMT1
GLM1
NR1C3
PPARG1
PPARG2
PPARgamma
peroxisome proliferator-activated receptor gamma PPARG protein affects the reaction [Lovastatin results in increased expression of PTEN protein] affects reaction
/ increases expression
protein 16425225
D008148 5728 PTEN
10q23del
BZS
CWS1
DEC
GLM2
MHAM
MMAC1
PTEN1
TEP1
phosphatase and tensin homolog (EC:3.1.3.67 3.1.3.16 3.1.3.48) Cycloheximide inhibits the reaction [Lovastatin results in increased expression of PTEN protein] decreases reaction
/ increases expression
protein 16425225
D008148 5728 PTEN
10q23del
BZS
CWS1
DEC
GLM2
MHAM
MMAC1
PTEN1
TEP1
phosphatase and tensin homolog (EC:3.1.3.67 3.1.3.16 3.1.3.48) Lovastatin results in increased expression of PTEN protein increases expression
protein 16425225
D008148 5728 PTEN
10q23del
BZS
CWS1
DEC
GLM2
MHAM
MMAC1
PTEN1
TEP1
phosphatase and tensin homolog (EC:3.1.3.67 3.1.3.16 3.1.3.48) PPARG protein affects the reaction [Lovastatin results in increased expression of PTEN protein] affects reaction
/ increases expression
protein 16425225
D008148 5743 PTGS2
COX-2
COX2
GRIPGHS
PGG/HS
PGHS-2
PHS-2
hCox-2
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) Lovastatin results in decreased expression of PTGS2 protein decreases expression
protein 21910007
D008148 5879 RAC1
Rac-1
TC-25
p21-Rac1
ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1) geranylgeraniol inhibits the reaction [Lovastatin affects the localization of RAC1 protein] affects localization
/ decreases reaction
protein 12933658
D008148 5879 RAC1
Rac-1
TC-25
p21-Rac1
ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1) Lovastatin affects the localization of RAC1 protein affects localization
protein 12933658
21356574
D008148 5879 RAC1
Rac-1
TC-25
p21-Rac1
ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1) Lovastatin results in decreased activity of RAC1 protein decreases activity
protein 19360310
D008148 5879 RAC1
Rac-1
TC-25
p21-Rac1
ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1) Lovastatin results in increased expression of RAC1 protein increases expression
protein 18766339
D008148 5879 RAC1
Rac-1
TC-25
p21-Rac1
ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1) Mevalonic Acid inhibits the reaction [Lovastatin affects the localization of RAC1 protein] affects localization
/ decreases reaction
protein 12933658
D008148 5894 RAF1
CRAF
NS5
Raf-1
c-Raf
v-raf-1 murine leukemia viral oncogene homolog 1 (EC:2.7.11.1) Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of RAF1 protein] decreases reaction
/ increases phosphorylation
protein 19760159
D008148 5894 RAF1
CRAF
NS5
Raf-1
c-Raf
v-raf-1 murine leukemia viral oncogene homolog 1 (EC:2.7.11.1) Lovastatin results in decreased activity of RAF1 protein decreases activity
protein 19360310
D008148 5906 RAP1A
KREV-1
KREV1
RAP1
SMGP21
RAP1A, member of RAS oncogene family Lovastatin results in increased expression of RAP1A protein increases expression
protein 12467231
D008148 5925 RB1
OSRC
RB
p105-Rb
pRb
pp110
retinoblastoma 1 Lovastatin results in decreased phosphorylation of RB1 protein decreases phosphorylation
protein 10502407
15118409
D008148 387 RHOA
ARH12
ARHA
RHO12
RHOH12
ras homolog family member A geranylgeraniol inhibits the reaction [Lovastatin affects the localization of RHOA protein] affects localization
/ decreases reaction
protein 12933658
D008148 387 RHOA
ARH12
ARHA
RHO12
RHOH12
ras homolog family member A Lovastatin affects the localization of RHOA protein affects localization
protein 12933658
D008148 387 RHOA
ARH12
ARHA
RHO12
RHOH12
ras homolog family member A Lovastatin results in decreased prenylation of RHOA protein decreases prenylation
protein 16156861
D008148 387 RHOA
ARH12
ARHA
RHO12
RHOH12
ras homolog family member A Mevalonic Acid inhibits the reaction [Lovastatin affects the localization of RHOA protein] affects localization
/ decreases reaction
protein 12933658
D008148 388 RHOB
ARH6
ARHB
MST081
MSTP081
RHOH6
ras homolog family member B Lovastatin results in decreased prenylation of RHOB protein decreases prenylation
protein 16156861
D008148 388 RHOB
ARH6
ARHB
MST081
MSTP081
RHOH6
ras homolog family member B Lovastatin results in increased expression of RHOB protein increases expression
protein 12467231
D008148 10599 SLCO1B1
HBLRR
LST-1
LST1
OATP-C
OATP1B1
OATP2
OATPC
SLC21A6
solute carrier organic anion transporter family, member 1B1 Lovastatin inhibits the reaction [SLCO1B1 protein results in increased transport of estradiol-17 beta-glucuronide] decreases reaction
/ increases transport
protein 15616150
D008148 10599 SLCO1B1
HBLRR
LST-1
LST1
OATP-C
OATP1B1
OATP2
OATPC
SLC21A6
solute carrier organic anion transporter family, member 1B1 Lovastatin results in decreased activity of SLCO1B1 protein decreases activity
protein 15616150
D008148 6721 SREBF2
SREBP-2
SREBP2
bHLHd2
sterol regulatory element binding transcription factor 2 Lovastatin results in increased localization of SREBF2 protein increases localization
protein 11728391
D008148 261729 STEAP2
IPCA1
PCANAP1
PUMPCn
STAMP1
STMP
STEAP family member 2, metalloreductase STEAP2 SNP results in decreased susceptibility to Lovastatin decreases response to substance
SNP 21483694
D008148 7038 TG
AITD3
TGN
thyroglobulin Lovastatin results in increased secretion of TG protein increases secretion
protein 12843138
D008148 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 Lovastatin inhibits the reaction [TGFB1 protein results in increased abundance of Reactive Oxygen Species] decreases reaction
/ increases abundance
protein 22129737
D008148 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 Lovastatin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] decreases reaction
/ increases expression
protein 22129737
D008148 7054 TH
DYT14
DYT5b
TYH
tyrosine hydroxylase (EC:1.14.16.2) Lovastatin results in increased expression of TH protein increases expression
protein 20694854
D008148 7054 TH
DYT14
DYT5b
TYH
tyrosine hydroxylase (EC:1.14.16.2) Mevalonic Acid inhibits the reaction [Lovastatin results in increased expression of TH protein] decreases reaction
/ increases expression
protein 20694854
D008148 8743 TNFSF10
APO2L
Apo-2L
CD253
TL2
TRAIL
tumor necrosis factor (ligand) superfamily, member 10 Lovastatin results in increased susceptibility to TNFSF10 protein increases response to substance
protein 17928957
D008148 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Lovastatin inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] decreases reaction
/ increases expression
protein 17088865
D008148 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Lovastatin results in increased expression of and results in increased phosphorylation of TP53 protein increases expression
/ increases phosphorylation
protein 21199873
D008148 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Lovastatin results in increased expression of TP53 mRNA increases expression
mRNA 21199873

Related Disease

Diseases related to proteins in ChEMBL interactions

OMIM (74)

OMIM preferred title UniProt
#100100 Abdominal muscles, absence of, with urinary tract abnormality and cryptorchidism P20309
#103780 Alcohol dependence P08172
P14416
P31645
#614373 Amyotrophic lateral sclerosis 16, juvenile; als16 Q99720
#602025 Body mass index quantitative trait locus 9; bmiq9 P41968
%606641 Body mass index; bmi P37231
#114480 Breast cancer P31749
#300615 Brunner syndrome P21397
#115200 Cardiomyopathy, dilated, 1a; cmd1a P02545
#212112 Cardiomyopathy, dilated, with hypergonadotropic hypogonadism P02545
#609338 Carotid intimal medial thickness 1 P37231
#605588 Charcot-marie-tooth disease, axonal, type 2b1; cmt2b1 P02545
#114500 Colorectal cancer; crc P31749
P84022
#615109 Cowden syndrome 6; cws6 P31749
#162800 Cyclic neutropenia P08246
#612522 Diabetes mellitus, insulin-dependent, 22; iddm22 P51681
#609535 Drug metabolism, poor, cyp2c19-related P33261
#608902 Drug metabolism, poor, cyp2d6-related P10635
#237500 Dubin-johnson syndrome; djs Q92887
#181350 Emery-dreifuss muscular dystrophy 2, autosomal dominant; edmd2 P02545
#615363 Estrogen resistance; estrr P03372
#600274 Frontotemporal dementia; ftd P10636
#613659 Gastric cancer P04626
#137215 Gastric cancer, hereditary diffuse; hdgc P04626
#231095 Ghosal hematodiaphyseal dysplasia; ghdd P24557
#137800 Glioma susceptibility 1; glm1 O75874
P04626
P37231
#610140 Heart-hand syndrome, slovenian type P02545
#609423 Human immunodeficiency virus type 1, susceptibility to P41597
P51681
#176670 Hutchinson-gilford progeria syndrome; hgps P02545
#237450 Hyperbilirubinemia, rotor type; hblrr Q9NPD5
Q9Y6L6
#603373 Hyperthyroidism, familial gestational P16473
#609152 Hyperthyroidism, nonautoimmune P16473
#275200 Hypothyroidism, congenital, nongoitrous, 1; chng1 P16473
#612244 Inflammatory bowel disease 13; ibd13 P08183
#603932 Intervertebral disc disease; idd P14780
#116920 Leukocyte adhesion deficiency, type i; lad P05107
#151660 Lipodystrophy, familial partial, type 2; fpld2 P02545
#604367 Lipodystrophy, familial partial, type 3; fpld3 P37231
#613795 Loeys-dietz syndrome, type 3; lds3 P84022
#613688 Long qt syndrome 2; lqt2 Q12809
#211980 Lung cancer P00533
P04626
#608516 Major depressive disorder; mdd P08172
#611162 Malaria, susceptibility to P05362
#248370 Mandibuloacral dysplasia with type a lipodystrophy; mada P02545
%300852 Mental retardation, x-linked 88; mrx88 P50052
#613073 Metaphyseal anadysplasia 2; mandp2 P14780
#126200 Multiple sclerosis, susceptibility to; ms P08575
#613205 Muscular dystrophy, congenital, lmna-related P02545
#159001 Muscular dystrophy, limb-girdle, type 1b; lgmd1b P02545
#607948 Mycobacterium tuberculosis, susceptibility to P11473
#159900 Myoclonic dystonia P14416
#202700 Neutropenia, severe congenital, 1, autosomal dominant; scn1 P08246
#601665 Obesity P32245
P37231
#164230 Obsessive-compulsive disorder; ocd P31645
#604715 Orthostatic intolerance P23975
#259730 Osteopetrosis, autosomal recessive 3; optb3 P00918
#167000 Ovarian cancer P04626
#260540 Parkinson-dementia syndrome P10636
#613135 Parkinsonism-dystonia, infantile; pkdys Q01959
#172700 Pick disease of brain P10636
#176920 Proteus syndrome P31749
#607276 Resting heart rate, variation in P08588
#275210 Restrictive dermopathy, lethal P02545
#608971 Severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-positive, nk cell-positive P08575
#609620 Short qt syndrome 1; sqt1 Q12809
#253300 Spinal muscular atrophy, type i; sma1 Q16637
#253550 Spinal muscular atrophy, type ii; sma2 Q16637
#253400 Spinal muscular atrophy, type iii; sma3 Q16637
#271150 Spinal muscular atrophy, type iv; sma4 Q16637
#607250 Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy; scan1 Q9NUW8
#601104 Supranuclear palsy, progressive, 1; psnp1 P10636
#190300 Tremor, hereditary essential, 1; etm1 P35462
#277440 Vitamin d-dependent rickets, type 2a; vddr2a P11473
#610379 West nile virus, susceptibility to P51681
#112100 Yt blood group antigen P22303

KEGG DISEASE (58)

KEGG disease name UniProt
H00016 Oral cancer P00533 (related)
P00533 (marker)
H00017 Esophageal cancer P00533 (related)
P35354 (related)
H00018 Gastric cancer P00533 (related)
P04626 (related)
H00022 Bladder cancer P00533 (related)
P04626 (related)
H00028 Choriocarcinoma P00533 (related)
P03956 (related)
P04626 (related)
H00030 Cervical cancer P00533 (related)
P04626 (related)
H00042 Glioma P00533 (related)
P00533 (marker)
H00055 Laryngeal cancer P00533 (related)
P00533 (marker)
H00241 Combined proximal and distal renal tubular acidosis (RTA type 3) P00918 (related)
H00436 Osteopetrosis P00918 (related)
H00264 Charcot-Marie-Tooth disease (CMT) P02545 (related)
H00294 Dilated cardiomyopathy (DCM) P02545 (related)
H00420 Familial partial lipodystrophy (FPL) P02545 (related)
P37231 (related)
H00563 Emery-Dreifuss muscular dystrophy P02545 (related)
H00590 Congenital muscular dystrophies (CMD/MDC) P02545 (related)
H00593 Limb-girdle muscular dystrophy (LGMD) P02545 (related)
H00601 Hutchinson-Gilford progeria syndrome P02545 (related)
H00663 Restrictive dermopathy P02545 (related)
H00665 Mandibuloacral dysplasia P02545 (related)
H01216 Left ventricular noncompaction (LVNC) P02545 (related)
H00026 Endometrial Cancer P03372 (marker)
P04626 (related)
Q92731 (marker)
H00599 46,XX disorders of sex development (Disorders related to androgen excess) P04150 (related)
H00019 Pancreatic cancer P04626 (related)
H00027 Ovarian cancer P04626 (related)
H00031 Breast cancer P04626 (related)
P04626 (marker)
H00046 Cholangiocarcinoma P04626 (related)
P35354 (related)
H00099 Leukocyte adhesion deficiency (LAD) P05107 (related)
H00083 Allograft rejection P05362 (related)
H00080 Systemic lupus erythematosus P05362 (marker)
H00093 Combined immunodeficiencies (CIDs) P06239 (related)
H00079 Asthma P07550 (related)
H00100 Neutropenic disorders P08246 (related)
H00091 T-B+Severe combined immunodeficiencies (SCIDs) P08575 (related)
H00036 Osteosarcoma P08684 (marker)
H00058 Amyotrophic lateral sclerosis (ALS) P10636 (related)
H00077 Progressive supranuclear palsy (PSP) P10636 (related)
H00078 Frontotemporal lobar degeneration (FTLD) P10636 (related)
H00342 Tuberculosis P11473 (related)
H00784 Localized autosomal recessive hypotrichosis P11473 (related)
H01143 Vitamin D-dependent rickets P11473 (related)
H01205 Coumarin resistance P11712 (related)
H00025 Penile cancer P14780 (related)
P35354 (related)
H00479 Metaphyseal dysplasias P14780 (related)
H00250 Congenital nongoitrous hypothyroidism (CHNG) P16473 (related)
H01269 Congenital hyperthyroidism P16473 (related)
H00548 Brunner syndrome P21397 (related)
H01031 Orthostatic intolerance (OI) P23975 (related)
H00490 Diaphyseal dysplasia with anemia (Ghosal) P24557 (related)
H00539 PTEN hamartoma tumor syndrome (PHTS) P31749 (related)
H01171 Poor drug metabolism (PM) P33261 (related)
H00032 Thyroid cancer P37231 (related)
H00409 Type II diabetes mellitus P37231 (related)
H00480 Non-syndromic X-linked mental retardation P50052 (related)
H00720 Long QT syndrome Q12809 (related)
H00725 Short QT syndrome Q12809 (related)
H00455 Spinal muscular atrophy (SMA) Q16637 (related)
Q16637 (related)
H00208 Hyperbilirubinemia Q92887 (related)
H00063 Spinocerebellar ataxia (SCA) Q9NUW8 (related)

Diseases related to CTD interactions

61 disease from interactions of metabolites

MeSH disease OMIM compound disease name evidence type reference
pmid
D058186 D008148 Acute Kidney Injury marker/mechanism
2253372
2297197
2355431
3275891
3290520
8767987
9350151
D000743 D008148 Anemia, Hemolytic marker/mechanism
7653497
D000799 D008148 Angioedema marker/mechanism
10084510
D000855 D008148 Anorexia marker/mechanism
7867482
D018771 D008148 Arthralgia marker/mechanism
8481075
D001930 D008148 Brain Injuries therapeutic
16400415
D002493 D008148 Central Nervous System Diseases marker/mechanism
15987932
D002779 D008148 Cholestasis marker/mechanism
2026107
8439902
D002780 D008148 Cholestasis, Intrahepatic marker/mechanism
7867482
D003110 D008148 Colonic Neoplasms therapeutic
10500066
10815931
D003324 D008148 Coronary Artery Disease therapeutic
11597936
D003866 D008148 Depressive Disorder therapeutic
12954916
D003882 D008148 Dermatomyositis marker/mechanism
8944218
D056486 D008148 Drug-Induced Liver Injury marker/mechanism
therapeutic
1559791
7867482
8999220
9350151
22331495
22712078
D064420 D008148 Drug-Related Side Effects and Adverse Reactions marker/mechanism
2017280
D004401 D008148 Dysarthria marker/mechanism
15596782
D050171 D008148 Dyslipidemias therapeutic
16230877
17319473
D001068 D008148 Eating Disorders marker/mechanism
7909021
D005076 D008148 Exanthema marker/mechanism
3055921
D005483 D008148 Flushing marker/mechanism
12685616
D005767 D008148 Gastrointestinal Diseases marker/mechanism
8481075
D006261 D008148 Headache marker/mechanism
8221476
D006330 D008148 Heart Defects, Congenital marker/mechanism
15987932
D006937 D008148 Hypercholesterolemia therapeutic
1521554
1682723
1985608
2017280
2067654
2247468
2492189
2572816
2572817
3275891
3290520
7484806
7653497
7867482
7942524
8172444
8221476
8238075
8360706
8439902
8480959
8481075
8593127
8918723
8944218
9244616
9350151
9514463
10084510
10360474
10815931
11058722
12139858
12467231
12933658
12954916
17049607
19027590
D006949 D008148 Hyperlipidemias therapeutic
1615846
2322916
8252847
9110123
12685616
18566298
D006938 D008148 Hyperlipoproteinemia Type II therapeutic
2026107
2492189
15159270
D006973 D008148 Hypertension therapeutic
7560723
D015228 D008148 Hypertriglyceridemia therapeutic
15159270
D006987 D008148 Hypesthesia marker/mechanism
7484806
10027656
D052456 D008148 Hypoalphalipoproteinemias therapeutic
8238075
D007565 D008148 Jaundice marker/mechanism
7867482
D041781 D008148 Jaundice, Obstructive marker/mechanism
2026107
2322916
D007676 D008148 Kidney Failure, Chronic marker/mechanism
8918723
D008103 D008148 Liver Cirrhosis therapeutic
22712078
D008223 D008148 Lymphoma therapeutic
15943032
D008325 D008148 Mammary Neoplasms, Experimental therapeutic
15180944
D017240 D008148 Mitochondrial Myopathies marker/mechanism
12353945
D019964 D008148 Mood Disorders marker/mechanism
8238075
D009069 D008148 Movement Disorders therapeutic
18434508
D009120 D008148 Muscle Cramp marker/mechanism
2572816
D018908 D008148 Muscle Weakness marker/mechanism
1521554
2572816
7484806
9244616
12353945
17049607
D009135 D008148 Muscular Diseases marker/mechanism
1985608
2067654
2355431
2572817
3055921
7650497
7942524
8360706
8480959
8481075
8729588
10217378
10799017
11058722
12139858
19027590
19496270
D009212 D008148 Myoglobinuria marker/mechanism
3076126
8360706
D009220 D008148 Myositis marker/mechanism
1615846
3275891
16089017
D009336 D008148 Necrosis marker/mechanism
9605009
18034278
D000857 D008148 Olfaction Disorders marker/mechanism
1388478
D009846 D008148 Oliguria marker/mechanism
8767987
D010146 D008148 Pain marker/mechanism
10217378
12353945
17200428
D010190 D008148 Pancreatic Neoplasms therapeutic
21491092
D010292 D008148 Paresthesia marker/mechanism
7484806
8172444
D010523 D008148 Peripheral Nervous System Diseases marker/mechanism
7484806
9671841
D011115 D008148 Polyneuropathies marker/mechanism
12011277
D011507 D008148 Proteinuria marker/mechanism
8225831
D051437 D008148 Renal Insufficiency marker/mechanism
3076126
8252847
8360706
D012206 D008148 Rhabdomyolysis marker/mechanism
2017280
2253372
2297197
2355431
3275891
3290520
8252847
8767987
8918723
9350151
D012509 D008148 Sarcoma therapeutic
10815931
15943032
D012817 D008148 Signs and Symptoms, Digestive marker/mechanism
3055921
D012893 D008148 Sleep Disorders marker/mechanism
7909021
8238075
D007319 D008148 Sleep Initiation and Maintenance Disorders marker/mechanism
3055921
8481075
D013733 D008148 Testicular Diseases marker/mechanism
17200428
D014581 D008148 Urticaria marker/mechanism
10084510